Baxter commences BAX 855 Phase We trial in hemophilia A Baxter International Inc.

This trial is made to provide brand-new insights about our investigational longer-performing FVIII molecule, BAX 855, with the best goal of improving look after patients coping with hemophilia A, stated Prof. Hartmut J. Ehrlich, M.D., vice president of global research and advancement in Baxter’s BioScience business. The Phase I outcomes will serve as the building blocks for advancing this essential program through clinical advancement and identifying whether BAX 855 can provide a treatment regimen needing fewer infusions than ADVATE. .. Baxter commences BAX 855 Phase We trial in hemophilia A Baxter International Inc. today announced the dosing of the initial patients in a Stage I scientific trial of its business lead investigational candidate, BAX 855, a longer-acting type of a full-size recombinant element VIII proteins.Not fast, says WHI research writer Dr. JoAnn Manson, the chair of preventive medication department at Brigham and Women’s Medical center in Boston. ‘This is a selective re-evaluation of particular subgroups of the WHI calcium and vitamin D trial,’ she says. ‘Overall, there is no evidence of an increase or reduction in risk for coronary heart disease or stroke with usage of calcium and vitamin D,’ she says. Also, another arm of the WHI, which looked at coronary artery calcium levels, showed no evidence of increased heart dangers among females who were randomly assigned to calcium plus vitamin D. Dr. Nieca Goldberg, medical director of the Women’s Heart System at NYU Langone Medical Center in New York, says women should be aware of just how much calcium they complete diet and just how much they complete supplements to avoid getting too much of this mineral.